Is DNLI or EDIT more undervalued in 2026?

CirclFi compares Denali Therapeutics Inc. (DNLI) and Editas Medicine, Inc. (EDIT) using 13 institutional-grade valuation models. DNLI has a Quality of Company score of 6.9/10 while EDIT scores 6.5/10.

Which is a better buy — DNLI or EDIT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DNLI and EDIT valuations compare?

DNLI at $21.04 and EDIT at $3.46 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DNLI vs EDIT Valuation Comparison 2026 — Intrinsic Value Analysis

DNLI

Biological Products, (No Diagnostic Substances)

Denali Therapeutics Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$21.04

Last close

Models

12/13

Active

EDIT

Biological Products, (No Diagnostic Substances)

Editas Medicine, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$3.46

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	DNLI Fair Value	DNLI Upside	EDIT Fair Value	EDIT Upside
Bayesian DCF	Intrinsic	$5.29	-74.9%	$1.06	-69.4%
Earnings Power Value	Intrinsic	$9.00	-54.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$5.90	-72.0%	$2.00	-42.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DNLI vs EDIT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DNLI vs EDIT — Which Stock Is More Undervalued?

DNLI scores higher with a 6.9/10 quality rating vs EDIT's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Denali Therapeutics Inc. (DNLI) and Editas Medicine, Inc. (EDIT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DNLI currently trades at $21.04 with a QOC of 6.9/10, while EDIT trades at $3.46 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).